Navigation Links
Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study

EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that all injections have been completed in the Phase II/III Study IT-A-008 investigating Isolagen Therapy(TM) for the treatment of moderate to severe facial acne scars. Further, approximately half of all of the study participants have completed the final observation visit. Isolagen anticipates the acne study will conclude in the first quarter of 2009.

"The second half of 2008 has been very productive for Isolagen as we continue to deliver on our clinical milestones on time and with positive results," said Declan Daly, Chief Executive Officer of Isolagen. "We previously announced positive top-line results from our pivotal Phase III wrinkle study and positive results from our open label Phase II study of the full face. We are very excited that our acne program is progressing on time and we believe the dermatology community will be very interested in this data early next year because of the unmet need for a minimally invasive acne scar treatment. Our current priority is to gain additional funding and secure a strategic partner to help us deliver on the exciting clinical promise of the Isolagen therapy in all of these areas."

About the Isolagen Process(TM) and Isolagen Therapy(TM)

The Isolagen Process(TM) is an innovative cellular processing system which creates a natural, living cell therapy. By multiplying a patient's own collagen-producing cells or fibroblasts into tens of millions of new cells, a personalized treatment is created which is then returned to the patient's skin. This treatment, known as the Isolagen Therapy(TM), is designed to improve skin damage caused by the normal effects of aging, sun damage, acne and burns.

About Isolagen, Inc.

Isolagen(TM), Inc. (Amex: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release, include, without limitation, the timely completion of the overall acne study, the timely completion of the Company's Phase III wrinkle study, and the Company's ability to raise additional funding, whether through strategic partners, financing, or otherwise. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, as well as other public filings with the SEC since such date.

SOURCE Isolagen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Isolagen, Inc. Postpones Annual Meeting
2. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
3. Isolagen Modifies Ongoing Clinical Program for Acne Scars
4. Isolagen Inc. to Present at the 26th Annual JPMorgan Healthcare Conference
5. Isolagen Inc. Promotes Declan Daly to Chief Executive Officer (CEO)
6. Isolagen, Inc. Receives Notification Letter from American Stock Exchange
7. Isolagen, Inc. Promotes Todd Greenspan to Chief Financial Officer (CFO)
8. Isolagen, Inc. Sells Switzerland Facility
9. Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex
10. Eligard(R) six-month formulation successfully completes European approval procedure
11. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/26/2015)... ... 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday sales ... Black Friday and Cyber Monday massage chair sales to receive the best ... low to find the best massage chair deals, they can see all of the ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers ... on mammography, according to a study published online in the journal Radiology. Researchers ... mammography may necessitate a change in treatment. , Breast MRI is the most ...
(Date:11/25/2015)... ... 25, 2015 , ... TyloHelo Inc , North America’s ... Sauna accessories help improve the bather experience in the sauna, and the accessories ... the purist looking for simplicity in design to accessories that encourage a greater ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
(Date:11/25/2015)... total global healthcare industry is expected to grow at a ... has the highest projected growth at 12.7%, and ... ), is second with growth projected at 11.5%. ... In 2013-2014, total government funded healthcare was nearly 68%. Federal ... in 2013-2014. In real terms, out of pocket expenditure increased ...
Breaking Medicine Technology: